Gapping down
News:
- MESO -5.3% (files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as treatment for severe congenital heart disease)
- PGY -4.4% (CFO departs; Evangelos Perros appointed Interim CFO)
- KRYS -2% (announces that the Company's Marketing Authorization Application to the European Medicines Agency's Committee for Medicinal Products for Human Use for VYJUVEK for the treatment of dystrophic epidermolysis bullosa has been validated and is now under CHMP review)
- GMAB -1.8% (regulatory updates from the U.S. FDA and European Medicines Agency for epcoritamab an investigational T-cell engaging bispecific antibody administered subcutaneously)
- NVO -0.8% (GAM Investments' Niall Gallagher aiming to lower stake in NVO according to Bloomberg)
Analyst comments:
- FL -3.4% (downgraded to Sell from Neutral at Citigroup)
- GEHC -3.3% (downgraded to Sell from Neutral at UBS)
- LCID -1.4% (downgraded to Hold from Buy at Needham)
- JAZZ -1.3% (downgraded to Neutral from Buy at UBS)
- CP -1% (downgraded to Hold from Buy at Deutsche Bank)
- GPK -0.8% (downgraded to Mkt Perform from Strong Buy at Raymond James)
- CNI -0.6% (downgraded to Hold from Buy at Deutsche Bank)